Sequenom Sees Steady Growth of MaterniT21 Test Despite Competition | GenomeWeb

Sequenom said this week that sales of its MaterniT21 test are continuing to grow despite the recent entry of two competitive tests on the market.

Speaking this week at the Jefferies Global Healthcare Conference in New York, CEO Harry Hixson said that as of the end of May, the accession rate for MaterniT21 was 60,000 tests per year.

Adoption is "increasing week by week," Hixson said, and "we are pleased with the uptake of the test." Additionally, the turnaround time is now one week, down from 10 days.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.